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Abstract: This study describes the clinical, genetic, and histopathological features in patients with
RPGR-associated retinal dystrophies. Nine male patients from eight unrelated families underwent
a comprehensive ophthalmic examination. Additionally, the histopathology of the right eye from
a patient with an end-stage cone-rod-dystrophy (CRD)/sector retinitis pigmentosa (RP) phenotype
was examined. All RPGR mutations causing a CRD phenotype were situated in exon ORF15.
The mean best-corrected visual acuity (BCVA, decimals) was 0.58 (standard deviation (SD)): 0.34;
range: 0.05–1.13); and the mean spherical refractive error was −4.1 D (SD: 2.11; range: −1.38 to −8.19).
Hyperautofluorescent rings were observed in six patients. Full-field electroretinography responses
were absent in all patients. The visual field defects ranged from peripheral constriction to central
islands. The mean macular sensitivity on microperimetry was 11.6 dB (SD: 7.8; range: 1.6–24.4) and
correlated significantly with BCVA (r = 0.907; p = 0.001). A histological examination of the donor
eye showed disruption of retinal topology and stratification, with a more severe loss found in the
peripheral regions. Reactive gliosis was seen in the inner layers of all regions. Our study demonstrates
the highly variable phenotype found in RPGR-associated retinal dystrophies. Therapies should be
applied at the earliest signs of photoreceptor degeneration, prior to the remodeling of the inner retina.
Keywords: retinitis pigmentosa; Retinitis Pigmentosa GTPase Regulator (RPGR), cone-rod dystrophy;
histopathology; retinal dystrophies; natural history; genotype-phenotype
1. Introduction
Retinitis pigmentosa (RP) is the most common inherited retinal dystrophy, affecting approximately
1 in 3000 individuals [1]. Its predominant feature is the irreversible loss of rod photoreceptors,
with secondary loss of cone photoreceptors. Patients therefore typically present with symptoms of
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nyctalopia and peripheral visual field constriction, prior to symptoms of central vision loss. X-linked RP
(XLRP) accounts for 5%–15% of all RP cases and is recognized as one of the most severe forms of RP [2,3].
Mutations in the RPGR gene are responsible for 70%–90% of all XLRP cases [4–6]. Symptom onset
in affected males starts in childhood years and is described to reach blindness within the 4th decade
of life [2,7,8]. Despite the X-linked inheritance of RPGR, female carriers may also be affected by
XLRP [9,10].
Other phenotypes caused by mutations in the RPGR gene include X-linked cone-rod dystrophies
(CRD) and cone dystrophies (CD), in which degeneration predominantly affects cones, with or without
the later involvement of rods [11]. Compared to XLRP, the age at onset is later in XL-CRD/CD,
typically starting around the 4th decade of life, with initial symptoms being visual acuity loss,
color vision defects, and variable photophobia [2,12].
The RPGR gene encodes the retinitis pigmentosa GTPase regulator (RPGR) protein and is able to
express multiple isoforms through alternative splicing. The most common protein isoforms found in the
retina are RPGRORF15 and, to a lesser extent, the constitutive protein RPGR1–19 [13,14]. The RPGRORF15
transcript, which is believed to play a key role in intraflagellar transport processes, contains exon 1–14
and exon ORF15, which is formed by alternatively spliced exon 15 and intron 15 [15]. Exon ORF15
consists of multiple acidic glutamate–glycine repeats, which promotes polymerase arrest and replication
slippage, thus making it a mutational hotspot for XLRP [16]. CRD/CD-disease causing variants in
RPGR are also located in the ORF15 region and are typically located at the 3′ end of exon ORF15 [17].
At present, no approved treatments for RPGR-associated retinal dystrophies are available.
Recent advances have been made in animal models using subretinal RPGR-mediated gene therapy,
which has shown an increase in structural and functional survival of photoreceptors [18,19].
These findings have paved the way for human RPGR-targeted gene therapy, and phase I/II/III clinical
trials are currently ongoing (NCT03252847, NCT03116113 and NCT03316560) [20]. To facilitate a better
understanding of RPGR-associated retinal dystrophies and in view of future therapies, this study
provides an extensive prospective phenotypic evaluation of patients harboring mutations in the RPGR
gene. In addition, we report the histological changes in the retina of a donor RPGR patient who had a
clinical diagnosis of advanced CRD.
2. Results
2.1. Clinical Examination
In total, nine male patients from eight different families underwent a clinical evaluation, with a
mean age of 30.2 years (standard deviation [SD]: 11.54; range: 17.8–48.9) at the most recent examination.
Patients had a diagnosis of RP (n = 8) or CRD (n = 1). Eight different mutations were found, which were
located in exon 1–14 (n = 3) or exon ORF15 (n = 5, including the CRD patient), and were generally
frameshift mutations (n = 6), followed by nonsense (n = 1) and missense (n = 1) mutations (Table S1).
An overview of the clinical findings is provided in Table 1.
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Table 1. Clinical characteristics of patients with RPGR-associated retinal dystrophies at the last examination.
Family-ID Age Age at
Onset
Initial
Symptom DD
BCVA SER Lens Status Fundus Features Goldmann Perimetry (V4e)
OD OS OD OS OD OS OpticPallor
Attenuated
Vessels Bone-Spicules
Other Relevant
Findings
Visual Field
Patterns
Retinal Seeing
Retinal Areas
(mm2) OD|OS
A-1 45 5 VF loss RP 0.05 0.05 −1.0 −2.75 MildPSC
Mild
PSC Yes Yes Yes
Bull’s eye
appearance of
macula
Central island
with peripheral
remnant
95.3 120.4
B-2 * 20 5 Nightblindness RP 0.80 1.00 −5.00 −5.13 Clear Clear Yes No Yes
Optic disc
drusen
Peripheral
constriction 532.7 481.0
B-3 * 20 6 Nightblindness RP 1.25 1.00 −1.88 −0.88 Clear Clear Yes No Yes
Optic disc
drusen
Central island
with peripheral
remnant
148.8 158.7
C-4 30 5 Nightblindness RP 0.36 0.38 −5.63 −4.88 Clear Clear Yes Yes Yes
Macular
atrophy Central islands 84.6 73.8
D-5 33 13 VF loss RP 0.66 0.52 −5.75 −4.38 Clear Clear Yes Yes Yes Patches ofpreserved RPE
Central island
with peripheral
remnant
279.5 247.6
E-6 22 5 Nightblindness RP 0.50 0.40 −4.13 −4.50 Clear Clear Yes Yes Yes
Epiretinal
membrane
Central island
with peripheral
remnant
115.2 101.83
F-7 18 5 Nightblindness RP 0.70 1.00 −8.88 −7.50 Clear Clear Yes Yes Yes RPE alterations
Midperipheral
scotoma 632.2 669.5
G-8 36 5 Nightblindness RP 0.10 0.10 −3.63 −3.25 Clear Clear Yes Yes Yes
Macular
atrophy Central island 24.8 39.2
H-9 49 48 VA loss CRD 0.80 0.72 −3.25 −1.50 Clear Clear Yes No No
Bull’s eye
appearance of
macula
Central
scotoma 1213.32 782.04
DD = diagnosis; BCVA = best-corrected visual acuity; OD = right eye; OS = left eye; SER = spherical refractive error; VF = visual field; RP = retinitis pigmentosa; PSC = posterior
subcapsular cataract; BS = bone-spicule-like pigmentation; NR = non-recordable responses; RPE = retinal pigment epithelium; VA = visual acuity; CRD = cone-rod dystrophy; HM = hand
movements; LP = light perception vision. BCVA is shown in Snellen decimals. Visual fields were digitized into retinal seeing areas. * Patient B-2 and B-3 are 2nd degree relatives.
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For RP patients, the mean age at onset was 6.1 years (SD: 2.8; range: 5.0–13.0), with initial symptoms
being nyctalopia (n = 6; 75%) or visual field loss (n = 2; 25%). The mean best-corrected-visual-acuity
(BCVA; decimals) was 0.57 (SD: 0.36; range: 0.05–1.13), and the mean spherical refractive error (SER)
ranged from−1.88 D to−8.19 D (mean: −4.32 D; SD: 2.15). Besides the extensive prospective phenotypic
evaluation, we were able to retrieve longitudinal BCVA data from the medical records of all patients
with a mean follow-up of 11.5 years. In patient A-1, visual acuity remained relatively stable until
the 4th decade of life, and declined afterwards. BCVA loss correlated significantly with increasing
age (r = −0.857; p = 0.008) in patients with RP. In the CRD patient (H-9), the loss of visual acuity was
the first symptom, which presented after the 4th decade of life. After initial presentation, BCVA loss
(from 0.85 to 0.76) was already seen in a short time span of 0.9 years. The course of the BCVA decline
of the entire cohort is presented in Figure 1.
Figure 1. Graph demonstrating the change in mean best-corrected visual acuity (BCVA) in relation to
the age in years of this cohort. Snellen BCVA data were transformed into logMAR values. Data from
the same subject are shown using interpolation lines connecting the points. All patients had a retinitis
pigmentosa phenotype, except for patient H-9, who exhibited a cone-rod dystrophy phenotype.
On fundoscopy, clinical hallmarks of RP, including optic disc pallor, vascular attenuation,
and bone-spicule-like hyperpigmentation, were observed to various degrees (Figure 2). Optic nerve
head drusen were seen in two patients. All patients showed macular abnormalities, ranging from
moderate retinal pigment epithelium (RPE) changes to profound atrophy. Regions of RPE atrophy on
fundus examination corresponded with the hypo-autofluorescent (hypo-AF) lesions seen on fundus
autofluorescence (FAF) imaging. A macular hyperautofluorescent (hyper-AF) ring was seen in five
out of eight RP patients. On spectral-domain optical coherence (SD-OCT) imaging, a common feature
in RP patients was the loss of the outer retinal bands (external limiting membrane, ellipsoid zone
and the inner/outer segments) in the retina peripheral of the central macula, with relative structural
and functional sparing of the central macula. In the CRD patient, central macular atrophy was
seen, with FAF showing a central hypo-AF area surrounded by a hyper-AF ring (Figure 2D). No
bone-spicules were seen in this patient. SD-OCT imaging showed a loss of outer retinal bands focused
at the (para)fovea. None of the patients had cystoid macular edema during examination.
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Figure 2. Color fundus photographs (scale bar = 1 mm) and corresponding fundus autofluorescence (FAF,
scale bar = 1 mm) and spectral-domain optical coherence tomography (SD-OCT, scale bar = 200 µm)
images of patients carrying mutations in the RPGR gene. (A) The right eye of patient A-1, with a
best-corrected visual acuity (BCVA) of 0.05, showing a tilted optic disc, vascular attenuation,
and bone-spicule hyperpigmentation in the midperiphery. Degenerative changes are seen across
the entire retina, with sparing of the central macula. An atrophic perifoveal ring is present, resembling
a bull’s eye maculopathy. Correspondingly, FAF imaging in this patient showed hypo-autofluorescent
(hypo-AF) lesions throughout the posterior pole, with sparing of the central macula, and some optic
disc drusen. On SD-OCT imaging, atrophy of outer retinal layers is observed, with some relative
preservation of the ellipsoid zone (EZ) at the fovea. (B) The composite fundus photograph of the left
eye of patient B-2 (BCVA of 0.9), showing optic nerve head drusen, normal vessels, and bone-spicule
hyperpigmentation in the periphery. FAF imaging showed hypo-AF regions along the vascular arcades
and far periphery. A macular hyperautofluorescent (hyper-AF) ring is observed, which matches the
extent of EZ loss seen on SD-OCT. (C) The right eye of patient C-4 (BCVA of 0.36) carrying the c.706C >
T (p.[Gln236*]) mutation. In addition to bone-spicule hyperpigmentation in the periphery, the fundus of
this patient also displayed atrophic changes in the macula. A hyper-AF ring was seen on FAF, encircled
by a hypo-AF ring, which corresponded with the loss of outer retinal bands on SD-OCT. (D) The right
eye of patient G-8, with a BCVA of 0.25. The accumulation of hyperpigmented clumps in the macular
region is observed, as well as outside the retinal vascular arcades. On FAF imaging, granular hypo-AF
lesions are seen in the posterior pole, and a large central hypo-AF area is seen. SD-OCT imaging shows
atrophy of retinal layers, with increased choroidal visibility. Remnants of the outer retinal bands are
present in the (para)fovea, together with hyperreflective elevations at the level of the retinal pigment
epithelium (RPE) that seem to correspond to the hyperpigmented deposits on fundus photography.
(E) The left eye of patient H-9 (BCVA of 0.76), with a cone-rod dystrophy phenotype. A bull’s eye
appearance is seen in the macula on fundus examination, without the presence of bone-spicule-like
deposits. Similar findings are seen on FAF imaging, with hyper-AF spot in the fovea, where the outer
retinal layers are relatively preserved on SD-OCT, surrounded by a hypo-AF ring of outer retinal and
RPE atrophy, which itself is surrounded by a hyper-AF ring.
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Full-field electroretinography (ffERG) responses were absent in all RP patients at the time of
examination. Based on previous electroretinography (ERG) data (available for 5 RP patients), the mean
age at which ERG amplitudes were found to be non-detectable was 11.6 years (SD: 6.7; range: 6.0–23.0).
In the CRD patient, photopic responses were more severely reduced than scotopic responses, consistent
with a CRD phenotype. We performed dark-adapted full-field stimulus thresholds (FST) testing in
six patients using white and chromatic stimuli (Table S2). The mean general FST sensitivity for the
white stimulus, averaged between eyes, was −31.1 dB (SD: 21.6; range: −61.0 to −8.9). The mean
blue-red difference was 11.2 dB (SD: 10.9; range: −1.0 to 21.9), with most patients demonstrating a
mixed rod-cone mediated response (n = 4, including the CRD patient) and two patients showing
a cone-mediated response. The size of visual fields on kinetic perimetry (V4e stimuli), averaged
between eyes, ranged between 42.0 and 997.7 mm2 (median: 153.8; interquartile range (IQR): 185.3),
which correlated with the age of the RP patients (Spearman’s rho = −0.714; p = 0.047). Visual field
abnormalities ranged from peripheral constriction to central islands in patients with RP, and a central
scotoma in the CRD patient (Table 1). In addition, we successfully performed microperimetry testing
in 16 eyes from nine patients (Table S2). Fixation stability was reported as stable (n = 12), relatively
unstable (n = 2), or unstable (n = 2); the latter being the case in both eyes from patient A-1 (Snellen BCVA
of 0.05 in both eyes). The stability of fixation, as measured using the 95% bivariate contour ellipse area
(BCEA) values, correlated with BCVA (r = −0.926; p = 0.003). The mean retinal sensitivity was 11.6
dB (SD: 7.8; range: 1.6–24.4), which significantly correlated with BCVA (r = 0.907; p = 0.001) and not
with the size of V4e retinal seeing fields (r = 0.553; p = 0.123). In RP patients with macular atrophy,
some residual sensitivity at the central macula could still be observed (Figure 3).
Figure 3. Multimodal imaging and microperimetry in the left eye of patient G-8 (best-corrected
visual acuity of the left eye: 0.10). (A) Microperimetry revealed reduced, but measurable sensitivity
(red and orange sensitivity points) at the central 2◦ of the fovea, with nearly a complete absence of
sensitivity outside this region (black sensitivity points). Superimposed microperimetry data on the
fundus autofluorescence (FAF) image demonstrated that loss of retinal sensitivity on microperimetry
aligned with hypo-autofluorescent lesions on FAF. Scale bar = 1 mm. (B) The corresponding fundus
image showed clinical hallmarks of retinitis pigmentosa and macular atrophy. Scale bar = 1 mm.
(C) Spectral-domain optical coherence tomography (SD-OCT) showed remnants of the outer retina at
the (para)fovea. Scale bar = 200 µm.
2.2. Retinal Histology
Medical records of the donor patient (I-10), carrying the p.Glu1031Glyfs*58 (c.3092del) RPGR
mutation, were obtained. First, available records of this patient were found at the age of 32, with BCVA
loss as initial symptom (BCVA OD: 0.5; BCVA OS: 0.63). ERG examination revealed non-detectable
photopic responses and reduced scotopic amplitudes, suggesting a CRD phenotype. Goldmann kinetic
perimetry (V4e stimulus) showed a superior hemifield defect (Figure 4C). BCVA remained relatively
stable, until the patient revisited the clinic at the age of 58 (BCVA OD: 0.3; BCVA OS: 0.5). Cataract
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surgery due to a posterior subcapsular cataract in the left eye resulted in the improvement of BCVA in
the left eye, but no BCVA improvement was seen in the right eye after uncomplicated cataract surgery.
The course of BCVA regression/improvement of this patient is shown in Figure 4A. The last ophthalmic
examination was available at the age of 89. At the last examination, only hand movements and light
perception were observed in the right and left eye, respectively. On fundus examination, peripapillary
atrophy extending to the macular region was seen. Bone-spicules were present mostly in the inferior
and nasal quadrants, suggesting a mixed CRD /sector RP phenotype (Figure 4B). The right eye of
patient I-10 was retrieved postmortem at the age of 94, and was prepared for histologic examination.
Figure 4. Clinical characteristics and postmortem histopathological examination in patient I-10 at the
age of 94, who carried the p.Glu1031Glyfs*58 (c.3092del) mutation in RPGR. (A) A line graph detailing
the best-corrected visual acuity (logMAR) course regression in this patient. A cataract extraction was
performed at the age of 66 (left eye; OS) and 74 (right eye; OD). For hand movement vision, light
perception vision, and no light perception, logMAR values of 2.7, 2.8, and 2.9 were used, respectively.
(B) A fundus examination of the right eye at age 89 showed a pale optic disc with extensive peripapillary
and macular atrophy. Retinal vessels were attenuated or obliterated. Bone-spicule-like pigmentation
is mainly seen in the inferior-nasal quadrant. The green line illustrates the spectral-domain optical
coherence tomography (SD-OCT) section line. Scale bar = 1 mm. (C) Goldmann kinetic perimetry at the
age of 67 showed a superior hemifield defect. (D) SD-OCT imaging revealed profound degeneration of
all retinal layers. Scale bar = 200 µm. (E) A macroscopic examination of the right eye. A schematic
drawing indicating the approximate macular (I) and peripheral (II and III) regions sectioned and
processed for further examination. (F) A section of the macular region (I) showing the loss of
photoreceptor segments and the closing of the subretinal space. The retinal pigment epithelium (RPE)
layer is atrophic, but still visible in this section (hematoxylin-eosin (H&E), 200×). (G) A complete
absence of photoreceptor outer segments and RPE cells is observed in this peripheral section (II).
The inner layers are highly atrophic and disorganized. The migration of RPE cells into retinal vessels is
shown (yellow arrowhead; H&E, 200×). (H) A clear disruption of the normal topology and stratification
is also seen in this section (III), although there are still some RPE cells remaining (red arrowhead
(H&E, 200×)). (I–K) A positive immunoreactivity for glial fibrillary acid protein (GFAP) is seen across
all retinal layers in both macular and peripheral regions (GFAP, 200×).
Int. J. Mol. Sci. 2020, 21, 835 8 of 14
Sections of the macular and peripheral regions were processed for microscopic examination.
Gross examination of the right eye showed bone-spicule-like pigmentation predominantly in the
inferonasal quadrant (Figure 4E). Due to profound atrophy in the macular region, it was difficult to
accurately distinguish and pinpoint the fovea. In all sections, degenerative changes and disorganization
of the retinal laminae were evident. In the macular sections, the loss of photoreceptor outer segments
was observed, which was accompanied by a reduction in the number of photoreceptor cells and the
closing of the subretinal space. While the retinal pigment RPE layer was atrophic, it was not entirely
lost in the macular region.
Peripheral regions showed more extensive retinal remodeling than the macular region, with severe
disruption of the normal topology and stratification. The complete loss of the photoreceptor layer
and a major reduction in the RPE layer was observed. Some remaining patches of the RPE layer
were still visible (Figure 4H, red arrowhead). In sections devoid of a pigmented RPE layer, RPE cells
migrated and accumulated around the retinal vessels in the inner retina (Figure 4G, yellow arrowhead).
Immunohistochemical staining showed positivity for glial fibrillary acid protein (GFAP) across the
entire retina, in both macular and peripheral sections (Figure 4I–K), signifying reactive gliosis.
3. Discussion
In this study, we describe the clinical and genetic characteristics ofRPGR patients at different stages
of disease based on extensive prospective structural and functional phenotyping. The patients in this
cohort demonstrated typical features of RP or CRD. An early onset of symptoms was present in patients
with RP, with initial symptoms being night blindness or peripheral visual field loss. As such, we found
moderate to severe concentric visual field defects in all patients. In contrast, the first symptoms
occurred at the age of 48 in the CRD patient. After the onset of the disease, BCVA gradually declined
in the majority of patients. The fastest BCVA decline was seen in patient A-1, who demonstrated a
rapid decline of BCVA after the 4th decade of life. A fundus examination revealed profound atrophy
in the macula of this patient. While macular involvement occurs early in CRD, it typically is not seen
in RP patients until end-stage disease [12,21]. Retinal imaging in this study showed RPE atrophy on
FAF in various patterns and the loss of outer retinal bands on SD-OCT, which were all consistent with
either an RP or CRD phenotype. A hyper-AF ring was found in six out of nine patients, including the
CRD patient. Previous studies have shown that the hyper-AF ring correlates with the presence of the
EZ band and demarcates the transition between healthy and affected retina [2,22,23]. The constriction
of this hyper-AF ring in RP indicates disease progression, whereas, conversely, the expansion of the
hyper-AF ring in CRD patients suggests disease progression [2,24].
Defining disease severity is essential for gene therapy trials, as preserved rods and cones
are required for successful subretinal delivery [25]. For the assessment of rod and cone function,
several functional and psychophysical measurement tools exist, and these methods were explored
in this study. Microperimetry measures the retinal sensitivity of the macular region and is able to
detect changes within a short time span [26]. In our cohort, we were able to detect retinal sensitivity
loss in all patients, which correlated with the loss of visual acuity. Patients with macular atrophy still
retained some residual function at the fovea, although severely reduced, which may be targeted for
treatment. The benefit of microperimetry in gene therapy trials is the ability to measure the individual
retinal points exposed to treatment and to correlate these with fundus locations. However, possible
challenges with microperimetry may arise when patients with end-stage disease are included in
clinical trials. Our study and others have found that fixation stability is correlated with visual
acuity [27,28]. Fixation·instability causes greater variation in measurements, which may impact the
repeatability and reliability of testing [27,28]. Therefore, inherent test-retest variation should be taken
into account when assessing retinal function with microperimetry. FST is a psychophysical test that
measures the sensitivity of the entire retina, even in those without adequate fixation capabilities, and‘in
patients who do not have measurable rod and cone ffERG responses [29,30]. Using FST, we found
mixed rod–cone-mediated responses in four patients (including the CRD patient), and cone-mediated
Int. J. Mol. Sci. 2020, 21, 835 9 of 14
responses in two RP patients. Patients with cone-mediated responses in our cohort showed macular
atrophy and widespread RPE loss, suggesting that cone-mediated responses are indicators for more
advanced disease stages of RP [29]. Other studies have shown a strong correlation between FST
and residual ffERG amplitudes, suggesting that FST can be a potential replacement for ERG [31,32].
In patients with RPGR-associated RP, ERG responses are often severely reduced or absent from an
early age, as was the case in our cohort, and may not be an optimal parameter for future trials.
FST could potentially replace ERG as a psychophysical outcome for future RPGR-related studies
and is especially useful in patients with severe disease and fixation instability. However, as FST
measures the entire retina, it is unable to localize the individual retinal areas mediating the responses.
Therefore, caution must be exercised when interpreting FST results in clinical trials, as they may not
co-localize with the area of treatment.
Some possible genotype–phenotype correlations could be identified within this cohort.
Nine different variants in RPGR were detected, including the mutation found in the donor patient
(I-10). Frameshift mutations were the most common mutation type and were mainly located in exon
ORF15. It is worth noting that the mutations causing CRD phenotypes, p.(Glu1031Glyfs*58, the eye of
patient I-10 in whom histopathological studies were performed) and p.(Glu1071Alafs*16, patient H-9),
were found at the 3′ of ORF15. Our data support previous studies that suggested that mutations at
the 3′ terminal of ORF15 cause predominant CRD phenotypes [4,17]. It is believed that frameshift
mutations in the exons that encode the N-terminal RCC1-like domain of RPGR are more prone to
nonsense-mediated decay (NMD), leading to lower levels of the transcript and may therefore be more
likely to cause severe RP phenotypes [4]. Furthermore, the N-terminal RCC1-like domain of RPGR is
shared between RPGRORF15 and RPGR1–19 isoforms. Since RPGR1–19 is also expressed in primary cilia,
it is believed that mutations in the N-terminal RCC1-like domain may lead to retinal degeneration
with ciliary abnormalities, as shown in previous studies [33–35]. This phenotype was not observed
in our cohort, although more thorough testing is required to confirm the absence of ciliary defects.
Mutations in ORF15 are located at the terminal exon and are less likely to result in NMD, resulting in
milder RP (towards the 5′ end) and CRD (towards the 3′ end) phenotypes [4,17]. This is not always the
case, as mutations located close to the downstream of ORF15 have also been reported to result in RP
phenotypes [2,36]. In some cases, ORF15 mutations even resulted in both RP and CRD phenotypes,
highlighting the potential influence of genetic and/or environmental modifiers on the phenotype [16].
We also evaluated the retinal histopathology of an affected 94-year old patient with an end-stage
CRD/sector RP phenotype. There have only been a few histopathologic studies on eyes from patients
with known RPGR mutations [37,38]. Similar to CRD patient H-9, initial symptoms presented at a much
later time, at the age of 32, than the RP patients in this cohort. The longitudinal BCVA follow-up of 57
years in this patient showed that visual acuity gradually deteriorated. Strikingly, fundus examination
in this patient showed extensive peripapillary atrophy and bone-spicule hyperpigmentation, mainly in
the nasal and inferior quadrants, corresponding with a superior hemifield defects on kinetic perimetry.
Predisposition for superior visual field loss has been described in patients with sector RP caused by
mutations in the RHO gene, and rarely in patients with RPGR mutations [25,39,40]. Sectoral changes
are believed to reflect a milder phenotype and can develop into a widespread disease when followed
over decades [39]. On histologic examination, we found a severely atrophic and disorganized retina in
all sections. There was a widespread loss of photoreceptors, more so in the peripheral retina than in the
macula, which may explain the remaining visual acuity of only hand movements in this patient’s right
eye. Immunohistochemical analysis showed an intense staining for GFAP across the entire inner retina
in the peripheral region, indicating the process of reactive gliosis by Müller cells [41]. Inner remodeling
is detrimental for the application of bionic (retinal chip) and biological (gene, optogenetic, or stem
cell) rescue strategies. These therapies rely on remaining target neurons and may have limited success
when glial seal formation has taken place [42,43]. Therapies should therefore preferably be applied
at the earlier signs of degeneration, prior to inner retinal remodeling. Interestingly, GFAP staining
was also seen in macular sections, which revealed less degeneration compared to peripheral sections
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and showed no bone-spicule-like deposits on fundus examination. This suggests that the remodeling
of the inner retina may already take place before clinical signs are observable on fundoscopy and
retinal imaging [43]. No clinical imaging techniques exist that can accurately track the earliest stages
of remodeling, which implicates the optimal timing for therapy [43]. The exact impact of retinal
remodeling and gliosis on the long-term efficacy of therapeutic strategies is still unclear and needs to
be further elucidated.
In conclusion, we present a comprehensive clinical, genetic, and histopathologic overview of
patients with RPGR-associated retinal dystrophies. The clinical presentation of RPGR-related retinal
dystrophies is highly variable, but genotype–phenotype correlations can be discerned. We found that
microperimetry and FST can be useful functional parameters for evaluation in future trials. In end-stage
disease, remodeling takes place also in the inner retina, which may precede clinically observable signs,
complicating future therapeutic strategies. Therefore, treatments should preferably be applied in an
early disease stage.
4. Materials and Methods
4.1. Clinical Examination
Male participants were ascertained from the RD5000 registry, which is a national registry for
inherited retinal dystrophies [44]. Comprehensive ophthalmologic assessment was performed at the
Leiden University Medical Center (LUMC), including the measurement of BCVA using the Early
Treatment of Diabetic Retinopathy Study (ETDRS) chart, slit-lamp examination, color vision testing
(Hardy-Rand-Rittler (HRR)), and fundus photography (Topcon TRC-50DX, Topcon Medical Systems,
Inc. Oakland, NJ, USA). SD-OCT and FAF imaging were performed using the Spectralis HRA+OCT
system (Heidelberg Engineering, Heidelberg, Germany).
ffERG was performed according to International Society for Clinical Electrophysiology of Vision
(ISCEV) standards. ffERG was not conducted in patients that were previously reported to have
non-recordable responses (n = 5). FST testing was performed in 6 patients using the Espion
ColordomeTM LED full-field stimulator (Diagnosys LCC, Lowell, MA, USA). Both eyes were tested,
first using the white stimulus, followed by red and blue stimuli. Thresholds were tested three times
for each color and were averaged to determine the final thresholds. The difference in thresholds
between blue and red stimuli determined whether responses were either: rod-mediated (difference
of > 22 dB), cone-mediated (difference of < 3 dB), or mixed (difference between 3 and 22 dB) [29].
Goldmann kinetic perimetry was performed using V4e stimuli, and visual fields were digitized using
a method previously used by Dagnelie [45]. In addition, microperimetry (MAIA, Centervue, Padova,
Italy) was performed in all patients, under mesopic conditions, by performing the “4–2 fixed protocol”
to minimize a learning effect, followed by the “4–2 strategy” protocol for formal testing.
The present study was approved by the Medical Ethics Committee of the Erasmus Medical Center
(MEC-2010-359, approval date: 10/04/2015), as well by the Local Review Board of the LUMC (P11.100,
approval date: 09/11/2015). Informed consent was retrieved for all participants, and the study adhered
to the tenets of the Declarations of Helsinki. When available, clinical data from medical records were
retrieved for longitudinal evaluation.
4.2. Retinal Histology
The right eye was obtained 15 h postmortem from a 94-year old male patient (I-10) with a confirmed
mutation in the RPGR gene. Prior written informed consent for organ and tissue use in research was
given by the donor. Relevant tissues were fixed in 4% paraformaldehyde for 24 h and embedded
in paraffin. The embedded blocks were cut at 4 µm sections and stained with hematoxylin-eosin.
For immunohistochemical staining, following deparaffinization, rehydration, and heat-induced epitope
retrieval, the tissue sections were incubated with primary glial fibrillary acid protein (GFAP; monoclonal
mouse antibody, clone 6f2; DakoCytomation, Glostrup, Denmark; dilution 1:400) for 30 min and were
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counterstained with hematoxylin [46]. The slides were externally validated using appropriate control
tissues and were reviewed by an ophthalmic pathologist (R.M.V).
4.3. Genetic Analysis
Genomic DNA was extracted from peripheral blood samples according to standard protocols.
Genetic analysis was performed at the Department of Clinical Genetics of the Amsterdam University
Medical Centers (Amsterdam UMC, The Netherlands), the Netherlands, and methods used have been
published previously [2,10,47]. The primers used in this study can be accessed upon reasonable request.
4.4. Statistical Analysis
Data were analyzed using Statistical Package for the Social Sciences version 25.0 (IBM Corp,
Armonk, NY, USA). Findings with a p-value of <0.05 were considered statistically significant.
Normally and non-normally distributed data were displayed as means with SD and medians with
IQR, respectively. Depending on the distribution, either a Pearson’s or Spearman’s test was performed
for correlation testing.
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Abbreviations
BCVA Best-corrected visual acuity
CD Cone dystrophy
CRD Cone-rod dystrophy
FAF Fundus autofluorescence
ffERG Full-field electroretinography
FST Full-stimulus threshold
GFAP Glial fibrillary acid protein
Hyper-AF Hyperautofluorescent
Hypo-AF Hypo-autofluorescent
IQR Interquartile range
RP Retinitis pigmentosa
RPE Retinal pigment epithelium
RPGR Retinitis Pigmentosa GTPase Regulator
SD Standard deviation
SD-OCT Spectral-Domain Optical Coherence Tomography
XLRP X-linked retinitis pigmentosa
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